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ABSTRACT
We recently showed that upregulation of a key oncogene FOXM1 precedes head and neck squamous cell carcinoma (HNSCC) malignancy. Furthermore, we also identified a centrosomal protein CEP55
and a DNA helicase/putative stem cell marker HELLS, which are both downstream targets of FOXM1.
In this study, we have investigated the expression profiles of CEP55 and HELLS using immunohistochemistry and quantified by digital densitometry in a tissue panel (20 samples) consisting of normal oral mucosa, dysplasias, HNSCC and lymph node metastasis (LnMet) samples.
Furthermore, we corroborated our findings using absolute real-time PCR (qPCR) on a panel of 12 primary normal human oral keratinocytes, 5 dysplasia and 10 HNSCC cell lines. Finally, we validated our study using bioinformatics microarray analysis on an independent HNSCC patient cohort (4 normal and 16 tumours). In normal oral mucosa, CEP55 protein was detected at very low level within the upper differentiated layers. In contrast, CEP55 was highly expressed in oral dysplasia whereas only moderate expression was detected in HNSCC and LnMet. Low level of HELLS expression was detected in the basal cell layer of the normal oral mucosa, moderate level was seen in dysplasia and high levels in both HNSCC and LnMet. These expression patterns were consistent with both qPCR data from the cell line panel and microarray data analysis of TNM-stage defined HNSCC samples confirming the progressive expression pattern of CEP55 and HELLS. To our knowledge, this is the first pilot study demonstrating that both CEP55 and HELLS mRNA and protein expression positively correlate with pre-malignancy and HNSCC progression. This study provides strong evidence that CEP55 and HELLS may be used in conjunction with FOXM1 as a biomarker set for early cancer detection and indicators of malignant conversion and progression.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the 6 th most common cancer worldwide and it has higher death rates than cancers of the colon, breast, vulva or melanoma. 1 In the UK, over 4700 new cases are reported annually. Its impact on health services, the patients, their families and society in general is financially crippling because of the cost of treatment and the effect on the patients' cosmetic appearance, speech and eating. In recent years, there has been evidence of an increasing rate of HNSCC incidence in several European countries probably due to the changing trends of alcohol and tobacco consumption and exposure, especially in females. 2 Because of late tumour detection coupled with high recurrence rate after treatment, the 5-year survival of patients remains poor (average 50%, depending on clinical stage at diagnosis). 1 This supports the need for better screening and diagnostic interventions to improve early detection of HNSCC.
The human transcription factor FOXM1 gene consists of 10 exons located on the 12p13.3 chromosomal band (telomeric position). Two exons, named exons Va and VIIa, also referred to as exon A1 (or rat exon 6) and A2 respectively, are alternatively spliced. 3, 4 FOXM1 has a role in cell cycle, DNA repair and maintenance of genomic stability. 5 We were the first to establish a link between FOXM1 and oncogenesis when we showed that FOXM1 was upregulated in basal cell carcinoma, 3 the most common type of cancer in Caucasians worldwide. Subsequent studies of FOXM1 in many different solid human cancer types confirmed its pivotal role in oncogenesis. 5, 6 We have recently reported that transcriptional upregulation of FOXM1 precedes malignancy in a number of solid human cancer types including oral, oesophagus, lung, breast, kidney, bladder and uterus. 7 It has been shown that FOXM1 interacts with the human papilloma virus (HPV) 16 E7 protein 8 and that HPV16 E6/E7 has been implicated in HNSCC. 9 It is likely that HPV may play a role in HPV-positive HNSCC through FOXM1 activation. However, it has been shown that the frequency of HNSCCs that have integrated HPV and express high levels E7 is only in the region of 4-16%. 10, 11 We have recently shown that aberrant upregulation of FOXM1 serves as a first oncogenic hit by destabilising the genome and subsequent activation of downstream targets which regulates cytokinesis (CEP55, centrosomal protein 55kDa) [12] [13] [14] and epigenetic/stem-cell factor re-programming (HELLS, helicase lymphoid specific) [15] [16] [17] [18] leading to malignant transformation (anchorage-independent growth) of a premalignant oral keratinocyte line (SVpgC2a). 7 However, the protein expression profiles of CEP55 and HELLS during HNSCC progression have not been described. In this study, we have characterised the expression patterns of CEP55 and HELLS using immunohistochemistry and digital densitometry to quantify their protein levels in an HNSCC progression tissue panel consisting of normal oral mucosa, dysplasias, HNSCC and lymph node metastasis (LnMet). We have complemented these findings using absolute real-time reverse transcription PCR (qPCR) on a panel of primary normal human oral keratinocytes, dysplasia and HNSCC cell lines. The data suggest that CEP55 and HELLS in combination with FOXM1 are early markers of cancer detection and they are also indicators of malignant conversion and progression.
MATERIALS & METHODS

Clinical Samples
The use of human tissue was approved by the relevant Research Ethics Committees at each institution. The present study involved 20 patients' formalin-fixed paraffin embedded (FFPE) archival tissues as previously described. 
Real-time absolute quantitative RT-PCR
Poly-A+ mRNA extraction, reverse transcription and real-time absolute quantitative PCR (qPCR) protocols are MIQE compliant 28 and were performed as described previously 7 using a LightCycler LC480 instrument (Roche Diagnostic). Primer sequences for FOXM1B, CEP55, HELLS and two stable reference genes (POLR2A and YAP1) were described previously. 7 Statistical analysis was performed using the GraphPad InStat software (V2.04a, GraphPad Software, San Diego, CA) for Student's t-test analysis.
Bioinformatics analyses of microarray data
FOXM1, CEP55
and HELLS endogenous mRNA levels were analysed using published microarray data in a study using normal oral mucosa and a panel of TNM-staged defined HNSCC tissues
29
. The microarray dataset (GDS1584) was obtained from the NCBI's Gene Expression Omnibus (GEO) database. The Affymetrix gene reference identification for FOXM1, CEP55 and HELLS are 202580_x_at, 218542_at and 220085_at, respectively. Gene expression levels were statistically analysed using Student's t-test in Microsoft Excel software.
RESULTS
Protein Expression patterns of CEP55 and HELLS during HNSCC progression
In order to validate our previous finding that CEP55 and HELLS are targets of FOXM1, we investigated the CEP55 ( immunostaining was detected in the middle/upper suprabasal layers (Fig. 1A ,B -Normal). As the staining was restricted only to the keratinised layers we believe that this may be non-specific staining.
In contrast, intense but heterogeneous nuclear and cytoplasmic CEP55 expression was detected in oral dysplasia within the basaloid suprabasal layers (Fig. 1A ,B -Dysplasia). Moderately upregulated level of cytoplasmic CEP55 protein was detected in HNSCC tissues (Fig. 1A ,B -HNSCC). In LnMet, CEP55 exhibits a heterogeneous expression pattern with higher cytoplasmis and nuclear protein levels detected along the periphery of tumour mass (Fig. 1A ,B -LnMet). Digital densitometry was used to quantify the levels of CEP55 expression where 6-10 digital images were captured and quantified from each tissue specimen. Individual data points for each tissue specimen were plotted as a scatter plot (Fig. 1C) and Box-and-Whisker plot (Fig. 1D ) to illustrate the distribution pattern of CEP55 protein expression across the tissue panel. Mean  SEM analysis plot (Fig. 1E) showed that CEP55 was significantly upregulated in dysplasia and HNSCC. The upregulation of CEP55 in LnMet was not significant due to tissue heterogeneity.
In normal oral mucosa, HELLS nuclear immunostaining was detected strictly within the basal layer of the oral mucosa epithelium ( Fig. 2A ,B -Normal). In oral dysplasia, HELLS nuclear expression was moderately upregulated and found throughout the basaloid layers ( Fig. 2A ,B -Dysplasia). High level of nuclear HELLS protein was detected in HNSCC tumour masses ( Fig. 2A,B -HNSCC) . In LnMet, HELLS exhibits a heterogeneous nuclear expression pattern ( Fig. 2A,B -LnMet). Individual data points for each tissue specimen were plotted as a scatter plot (Fig. 2C) and Box-and-Whisker plot ( Fig.   2D ) as described above for CE55 expression. The mean expression  SEM analysis plot (Fig. 2E) showed that HELLS was significantly upregulated in all three disease tissues with a progressive trend.
Correlation of CEP55 and HELLS mRNA expression with FOXM1
It has been previously established that FOXM1B shows a progressive expression pattern during HNSCC progression. VB6, CaLH2, CaDec12, 5PT and H357) using absolute qPCR. Both CEP55 (Fig. 3A) and HELLS (Fig. 3B) showed good expression correlation with FOXM1B across the panel of cell lines used.
Bioinformatics microarray analysis of CEP55 and HELLS expression
To further validate the above findings, we performed bioinformatics analysis on an independent HNSCC patient cohort comparing 4 normal oral mucosa and 16 TNM-stage defined HNSCC samples. 29 The gene expression data of CEP55 and HELLS were extracted from the microarray dataset (GDS1584) using the NCBI's Gene Expression Omnibus online research tool as described previously. 7 The expression patterns of FOXM1, CEP55 and HELLS all showed similar bell-shaped profile across the different TNM tumour stages (Fig. 1C) with peak expression at early-mid tumour stages (T1N2bM0 to T4N2bM0) and decrease expression found in more advance tumour stages (T4N2M0 and T4N3M0). Statistical analysis showed that FOXM1 and CEP55 were significantly upregulated in the HNSCC (n=16) compared to normal tissues (n=4) (Fig. 3D) . The upregulation of HELLS expression in HNSCC was not statistically significant due to a greater heterogeneous gene expression within the different HNSCC tumour stages.
DISCUSSION
It is now well established that FOXM1 is a major oncogene in myriad of human cancers including HNSCC. 7, 30 In our previous study, we identified CEP55 and HELLS as two downstream targets of FOXM1. 7 Herein, we have provided the first protein expression evidence that both CEP55 and HELLS are differentially expressed during tumour progression from dysplasia to HNSCC and LnMet in human oral tissues. Both their expression patterns correlated well with that of FOXM1 expression profile across a cell line panel containing normal oral keratinocytes, dysplasia and HNSCC derived cells. The progressive pattern of gene expression of CEP55 and HELLS was further validated using bioinformatics microarray data analysis on an independent cohort of HNSCC study.
CEP55 is a microtubule-bundling protein that localizes to the mitotic spindle during prometaphase and metaphase and to the spindle midzone and the midbody during anaphase and is required for the completion of cytokinesis. [12] [13] [14] Consistent with CEP55 being a direct transcriptional target of FOXM1, 7 both CEP55 12 and FOXM1 31 share organ-specific expression in the testis and thymus of normal adult humans. CEP55 is upregulated in hepatocellular carcinoma and its overexpression induces anchorage-independent growth, enhanced cell growth at low serum levels and induction of tumourigenesis in nude mice. 32 Another study showed that CEP55 was overexpressed in lung cancer and is associated with cell migration and invasion. 33 Consistent with a role in malignancy, similar to the expression of FOXM1, 7 we found that CEP55 expression is significantly upregulated in both oral dysplasia and HNSCC tissues. Interestingly, a study involving 3 independent breast cancer patient cohorts of microarray datasets containing a total of 699 patients revealed that CEP55 and FOXM1 are amongst the signature prognostic markers which predict poor breast cancer outcome. 34 47 and melanoma. 48 HELLS was recently identified as one of the consensus genes expressed in human embryonic stem cells. 17 Recently, DNA methyltransferase 1 (DNMT1), an interacting partner of HELLS, 42 was shown to maintain progenitor function in self-renewing epidermis 49 highlighting a role for HELLS in progenitor cell maintenance and renewal. Interestingly, in the present study, HELLS expression was strictly restricted to the basal layer of the normal mucosa epithelium and that upregulation of HELLS was found in the hyperplastic basal and suprabasal layers in oral dysplasia.
This pattern of HELLS expression appear highly similar to that of FOXM1 immunostaining in basal cell carcinomas 3 and in HNSCC. 7 We therefore speculate that the upregulation of HELLS (and FOXM1) in HNSCC may indicate a deregulation of progenitor cell maintenance leading to hyperproliferation and tumour development.
In summary, this study provided the first evidence that a novel set of proliferation-associated genes FOXM1, CEP55 and HELLS share progressive expression pattern during the progression of HNSCC.
The fact that upregulation of these three genes precedes HNSCC malignancy renders them potential 
